NASDAQ:FBIO Fortress Biotech (FBIO) Stock Price, News & Analysis $2.27 +0.03 (+1.34%) Closing price 04:00 PM EasternExtended Trading$2.22 -0.04 (-1.98%) As of 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Fortress Biotech Stock (NASDAQ:FBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Fortress Biotech alerts:Sign Up Key Stats Today's Range$2.18▼$2.2950-Day Range$1.71▼$2.2552-Week Range$1.33▼$2.36Volume310,904 shsAverage Volume273,570 shsMarket Capitalization$67.54 millionP/E RatioN/ADividend YieldN/APrice Target$16.50Consensus RatingBuy Company Overview Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida. Read More Fortress Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreFBIO MarketRank™: Fortress Biotech scored higher than 53% of companies evaluated by MarketBeat, and ranked 535th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingFortress Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageFortress Biotech has only been the subject of 1 research reports in the past 90 days.Read more about Fortress Biotech's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Fortress Biotech are expected to grow in the coming year, from ($3.28) to ($1.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fortress Biotech is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fortress Biotech is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFortress Biotech has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.10% of the float of Fortress Biotech has been sold short.Short Interest Ratio / Days to CoverFortress Biotech has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.Change versus previous monthShort interest in Fortress Biotech has recently decreased by 4.79%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFortress Biotech does not currently pay a dividend.Dividend GrowthFortress Biotech does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.10% of the float of Fortress Biotech has been sold short.Short Interest Ratio / Days to CoverFortress Biotech has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.Change versus previous monthShort interest in Fortress Biotech has recently decreased by 4.79%, indicating that investor sentiment is improving. News and Social Media2.1 / 5News Sentiment-0.19 News SentimentFortress Biotech has a news sentiment score of -0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Fortress Biotech this week, compared to 1 article on an average week.Search Interest8 people have searched for FBIO on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.MarketBeat Follows2 people have added Fortress Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Fortress Biotech insiders have not sold or bought any company stock.Percentage Held by Insiders27.90% of the stock of Fortress Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.51% of the stock of Fortress Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fortress Biotech's insider trading history. Receive FBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address FBIO Stock News HeadlinesRoth Capital Expects Increased Earnings for Fortress BiotechAugust 22 at 2:13 AM | americanbankingnews.comFortress Biotech price target lowered to $17 from $26 at H.C. WainwrightAugust 21 at 1:04 PM | msn.comTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.August 22 at 2:00 AM | Porter & Company (Ad)Journey Medical Corporation to Present at the Emerging Growth ConferenceAugust 18, 2025 | globenewswire.comFortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate HighlightsAugust 14, 2025 | globenewswire.comJourney Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate HighlightsAugust 12, 2025 | globenewswire.comFortress Biotech (FBIO) Expected to Announce Quarterly Earnings on TuesdayAugust 11, 2025 | americanbankingnews.comJourney Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11August 7, 2025 | globenewswire.comSee More Headlines FBIO Stock Analysis - Frequently Asked Questions How have FBIO shares performed this year? Fortress Biotech's stock was trading at $2.03 at the start of the year. Since then, FBIO stock has increased by 11.3% and is now trading at $2.2590. How were Fortress Biotech's earnings last quarter? Fortress Biotech, Inc. (NASDAQ:FBIO) issued its quarterly earnings data on Thursday, August, 14th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.15. The biopharmaceutical company earned $16.41 million during the quarter, compared to analysts' expectations of $14.53 million. Fortress Biotech had a negative trailing twelve-month return on equity of 301.81% and a negative net margin of 24.84%. When did Fortress Biotech's stock split? Shares of Fortress Biotech reverse split on Tuesday, October 10th 2023.The 1-15 reverse split was announced on Monday, October 9th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Fortress Biotech's major shareholders? Fortress Biotech's top institutional investors include Shikiar Asset Management Inc. (0.94%), Envestnet Asset Management Inc. (0.57%), 180 Wealth Advisors LLC (0.31%) and Atria Investments Inc (0.30%). Insiders that own company stock include Lindsay A Md Rosenwald, Dov Klein and David Jin. View institutional ownership trends. How do I buy shares of Fortress Biotech? Shares of FBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Fortress Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fortress Biotech investors own include Plug Power (PLUG), FuelCell Energy (FCEL), Workhorse Group (WKHS), KALA BIO (KALA), Ovid Therapeutics (OVID), Lipocine (LPCN) and Comtech Telecommunications (CMTL). Company Calendar Last Earnings8/14/2025Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:FBIO CIK1429260 Webwww.fortressbiotech.com Phone(781) 652-4500Fax781-652-4545Employees170Year FoundedN/APrice Target and Rating Average Price Target for Fortress Biotech$16.50 High Price Target$17.00 Low Price Target$16.00 Potential Upside/Downside+643.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$46 million Net Margins-24.84% Pretax Margin-150.15% Return on Equity-301.81% Return on Assets-27.48% Debt Debt-to-Equity Ratio1.34 Current Ratio1.92 Quick Ratio1.55 Sales & Book Value Annual Sales$59.30 million Price / Sales1.11 Cash FlowN/A Price / Cash FlowN/A Book Value$1.26 per share Price / Book1.76Miscellaneous Outstanding Shares29,755,000Free Float21,453,000Market Cap$66.06 million OptionableOptionable Beta1.76 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:FBIO) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fortress Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fortress Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.